Antipsychotic-induced priapism in an HIV patient: a cytochrome P450-mediated drug interaction by Matthew J. Geraci et al.
ORIGINAL RESEARCH ARTICLE
Antipsychotic-induced priapism in an HIV patient:
a cytochrome P450-mediated drug interaction
Matthew J. Geraci & Stacey L. McCoy & Paul M. Crum &
Rajnikant A. Patel
Received: 20 April 2009 /Accepted: 25 February 2010 /Published online: 26 May 2010
# Springer-Verlag London Ltd 2010
Abstract
Background With upwards of 48% of human immunodefi-
ciency virus (HIV)-infected persons having a probable
psychiatric disorder, the possibility of cross-class drug
interactions causing adverse effects or fatalities exists.
Aims This report discusses an emergent case of low-flow
priapism caused by an interaction between a previously
prescribed combination protease inhibitor (PI) and newly
added antipsychotic medications.
Methods A 50-year-old HIV-positive man on highly active
antiretroviral therapy (HAART), including the combination
PI, lopinavir/ritonavir (Kaletra®), experienced an episode of
priapism hours after beginning two new antipsychotic
medications. Quetiapine (Seroquel®) and perphenazine
(Trilafon®) were added to treat a diagnosed schizoaffective
disorder.
Results The patient presented to the emergency department
complaining of a constant, painful erection lasting approx-
imately 42 h. Treatment with intracavernous ephedrine,
irrigation, and aspiration helped achieve detumescence.
Conclusion This case displays the immediate and detri-
mental effects due to the addition of antipsychotic medi-
cations to previously altered cytochrome P450 (CYP450)
enzyme levels. The inhibition of CYP450 enzymes 3A4
and 2D6 by the combination PI, lopinavir/ritonavir, was
likely the major culprit in causing greater than expected
free levels of perphenazine and quetiapine resulting in
priapism.
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Introduction
The employment of highly active antiretroviral therapy
(HAART) has raised interest and awareness in the human
immunodeficiency virus (HIV) psychopharmacology arena
due to potential drug-drug interactions. There is also a lack
of data and documented clinical studies with regards to the
wide range of adverse effects and combinations of these
medications. As upwards of 48% of HIV-infected persons
have a probable psychiatric disorder, the possibility of
cross-class drug interactions causing adverse effects or
fatalities exists [1, 2]. Undesirable symptoms or peculiar
presentations may be an indication that pharmaceutical
treatments may be counterproductive, requiring healthcare
professionals to investigate drug therapy. The following
describes a case of drug-induced low-flow priapism
provoked by the addition of new antipsychotic medications
to an HIV patient previously on HAART.
The cytochrome P450 (CYP450) family of enzymes has
been implicated in a large number of preventable, adverse
drug interactions when individually discussing HIV and
psychopharmacology. HAART can pose significant side
effects for patients and alter CYP450 metabolism exten-
sively; however, when combined with antipsychotic drugs
that require CYP450 enzymes for transport and metabo-
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lism, serum levels of assorted drugs can vary greatly often
resulting in serious adverse affects [1–3]. Pharmacokinetic
interactions among antiretroviral agents may influence the
potency or toxicity of co-administered drugs, such as the
addition of new antipsychotics to this patient’s regimen.
This case of low-flow priapism, a urologic emergency,
required immediate and aggressive management and may
prove to cause lasting urologic and sexual dysfunction.
Prior cases of antipsychotic-induced priapism have been
reported; however, this is the first reported case of priapism
associated with a likely drug interaction between antipsy-
chotics and protease inhibitors (PIs).
Case
A 50-year-old African-American man presented to the
emergency department (ED) in acute pain due to a
protracted case, approximately 42 h, of untreated priapism.
The patient has been HIV positive since 1996. He stated he
has taken HIV medications for many years and is extremely
adherent to his regimen. Current medications included a
multi-drug antiretroviral regimen including the combination
PI, lopinavir/ritonavir (Kaletra®, Abbott Labs) 200/50 mg
two tablets twice daily and the combination reverse
transcriptase inhibitor abacavir/lamivudine/zidovudine
(Trizivir, GlaxoSmithKline) 300/150/300 mg two tablets
daily. The patient was diagnosed with schizoaffective
disorder and was started on a regimen including two
antipsychotics, quetiapine (Seroquel®, AstraZeneca)
300 mg, three tablets at bedtime, and perphenazine
(Trilafon®, Schering-Plough) 8 mg by mouth nightly
administered two days prior. His prescribing physician also
added benztropine (Cogentin®, Merck) 1 mg by mouth
twice daily to abate extrapyramidal symptoms secondary to
antipsychotic therapy. The patient began taking these new
antipsychotic medications 48 h prior to presenting. Five to
six hours after taking his new medication the patient stated
the occurrence of a lasting non-stimulated erection. The
patient did not attempt to self-treat, seek medical advice, or
take any medications for his condition until he presented to
the hospital.
The ED work-up verified the patient’s history. He had no
record of prior erectile disturbances or priapism, sickle cell
disease, oncologic malignancies, blood dyscrasias, or pelvic
injury. Physical examination revealed an erect shaft with
soft glans, indicating a low-flow priapism. The patient
expressed that he had been on various medications over the
years with no history of priapism. He is compliant with his
current regimen and recently started new medications for
his psychological issues. The patient denied use of any
illicit drugs, over-the-counter (OTC) products, herbal
medications, and/or vasoactive medications for erectile
dysfunction. Medication history was verified by a call to
the patient’s local retail pharmacy where medications,
doses, and frequencies were verified. The patient verbalized
that the erection began approximately 5–6 h after the initial
dose of his new medications. He did not attempt to seek
care or treatment until the pain became unbearable. No
other antipsychotic-related side effects were present.
Initial laboratory work-up included a basic metabolic
panel (BMP) and complete blood count (CBC) both of
which were unremarkable. He was treated with intravenous
hydromorphone (Dilaudid®) and ondansetron (Zofran®) to
treat pain and nausea. He was later given oral hydrocodone
with acetaminophen (Lortab®) for pain. A urology consult
was ordered. Upon arrival the urologist examined the
patient and determined a course of action. The corpus
cavernosum was locally anesthetized with lidocaine 1%
with epinephrine and irrigated with dilute ephedrine and
saline. Due to the extended period of engorgement, multiple
attempts at irrigation and drainage with non-heparinized
saline and dilute ephedrine were made to reduce the blood
volume. Eventually detumescence was achieved after
aspiration of over 60 ml of blood. A post-procedure urine
sample was obtained before the patient was discharged
home. Urine toxicology test determined the patient was
positive for opiates and tricyclic antidepressants, while
negative for any recreational or drugs of abuse. Opioid
metabolites were most likely from the hydromorphone and
hydrocodone given for pain. Tricyclic metabolites in the
urine confirm the use of quetiapine. No other records of
possible medications for these positives results were
obtained from the patient’s local retail pharmacy.
Discussion
There is no way to foresee which patients will develop
priapism. The only predictor of it may be a history of
previous prolonged painless erections, which can lead to a
painful, damaging event. Priapism can occur with initial
doses of antipsychotics, after years of use, or with the
addition of new medications to a patient’s regimen [4].
Low-flow priapism, although rare (less then 1% occur-
rence), can be an adverse event of antipsychotic agents
resulting from a proposed blocking action at α-adrenergic
receptors. This α-blockade causes venous constriction and
prevents blood return to circulation [5–12]. Previous
management of patients with priapism due to antipsychotics
involved reducing the dose of the offending agent or
changing the medication to one with a lower α-adrenergic
affinity. This management style assumes that priapism can
be a dose-related function of the prescribed medication.
CYP450 enzymes are proteins produced in the liver,
responsible for the oxidative metabolism of drugs. Various
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medications have the ability to induce or inhibit one or many
of the CYP450 enzymes. This induction or inhibition can
cause unforeseen variances in drug metabolism, adverse
events, and therapeutic failures. Concomitant administration
of inducers or inhibitors with other drugs that are metabolized
by the CYP450 system can result in altered metabolism and
kinetics throughout the body. Many well-known drugs alter
P450 enzyme levels. Most CYP450 drug interactions can be
managed through vigilance and dose adjustment.
In examining the PIs affinity for CYP450 enzymes,
lopinavir is a substrate of the enzyme CYP3A4, while
ritonavir is a substrate of CYP1A2, 2B6, 2D6, and 3A4.
Ritonavir also is a strong inhibitor of CYP2C8, 2D6, and
3A4. Due to the fact that perphenazine is a major substrate
of CYP2D6, levels can be increased by 2D6 inhibitors,
such as ritonavir. Quetiapine binds to CYP3A4 and 2D6 as
a substrate; the PIs inhibit and also bind to 3A4 and 2D6
creating a larger amount of active quetiapine in the serum.
The combination of these drugs increases the free amount
of both perphenazine and quetiapine in the blood, predis-
posing the patient to possible toxicity and unwanted side
effects, such as priapism (see Table 1) [12].
Harrison et al. encountered a case of priapism in an HIV
patient due to quetiapine and reported the possibility of a
drug interaction due to illicit amphetamine use [7]. Their
case made no mention of any antiretroviral medication or PI
their patient used, so a correlation between PI use and
quetiapine could not be made. The current patient did not
have any amphetamines in his system, as verified by a post-
procedure urine toxicology screen. A review conducted by
Sood et al. states that priapism, although rare, can occur
with all atypical-antipsychotic medications [4]. As stated
above, priapism can occur with initial doses, after years of
use, or with the addition of new medications to a regimen.
In reviewing 50 publications and cases regarding priapism
and drug-drug reactions, there is no mention of priapism
due to the combination of HAART medications and
antipsychotics. Although the possibility exists that the
patient would have developed priapism using one or both
of the antipsychotics as a single agent, the immediate onset
of this situation was enhanced and is most likely fully to
blame upon previously altered CYP450 enzyme levels due
to the HAART, specifically the patient’s PI.
The Naranjo algorithm is a questionnaire designed to
determine the likelihood of whether an adverse drug
reaction is actually due to the drug rather than the result
of other factors. It is the most widely used algorithm to
assess such events and has been tested for internal validity
Table 1 CYP450 enzyme characteristics by medication [12]
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with between-rater reliability testing, and its probability
scale has consensual, content, and concurrent validity as
well as ease of use [13, 14]. The Naranjo algorithm rates
this drug interaction as “probable.”
Conclusion
Though a paucity of definitive data from controlled studies
regarding interactions between HAART medication and
antipsychotics exists, CYP450 enzyme disturbances are
documented within each drug class. This case demonstrates
the immediate and detrimental effects due to the addition of
antipsychotic medications to previously altered CYP450
enzyme levels. The CYP450 inhibition of enzymes 3A4 and
2D6 by the combination PI, lopinavir/ritonavir, is likely the
major culprit in causing increased free levels of perphenazine
and quetiapine. The immediate high level of free drug caused
an α-blockade resulting in priapism shortly after ingesting the
new antipsychotics. Clinicians should be aware of this rare but
potentially serious adverse event. Further investigation is
warranted regarding potential interactions between HAART
and antipsychotic medications to elucidate potential mecha-
nisms of adverse effects.
Author’s contributions All authors contributed substantially to the
report and its revision.
Conflict of interest None.
Funding No grants, financial support, or compensation has been
provided for this work.
References
1. Repetto MJ, Petitto JM (2008) Psychopharmacology in HIV-
infected patients. Psychosom Med 70(5):585–592
2. Ferrando SJ, Wapenyi K (2002) Psychopharmacological treatment
of patients with HIV and AIDS. Psychiatr Q 73(1):33–49
3. Sikka R, Magauran B, Ulrich A, Shannon M (2005) Bench to
bedside: pharmacogenomics, adverse drug interactions, and the
cytochrome P450 system. Acad Emerg Med 12(12):1227–1235
4. Sood S, James W, Bailon MJ (2008) Priapism associated with
atypical antipsychotic medications: a review. Int Clin Psycho-
pharmacol 23(1):9–17
5. Casiano H, Globerman D, Enns MW (2007) Recurrent priapism
during treatment with clozapine, quetiapine and haloperidol. J
Psychopharmacol 21(8):898–899
6. Davol P, Rukstalis D (2005) Priapism associated with routine use
of quetiapine: case report and review of the literature. Urology 66
(4):880
7. Harrison G, Dilley JW, Loeb L, Nelson K (2006) Priapism and
quetiapine in an HIV-positive male. J Clin Psychopharmacol 26
(1):100–101
8. Pais VM, Ayvazian PJ (2001) Priapism from quetiapine overdose:
first report and proposal of mechanism. Urology 58(3):462
9. Prado MJA, Formoso MV (2006) Priapism associated with
quetiapine in an elderly patient. Actas Esp Psiquiatr 34(3):209–
210
10. Chan J, Alldredge BK, Baskin LS (1990) Perphenazine-induced
priapism. DICP 24(3):246–249
11. Tejera CA, Ramos-Lorenzi JR (1992) Priapism in a patient
receiving perphenazine. J Clin Psychopharmacol 12(6):448–449
12. Lacy C, Armstrong L, Goldman M, Lance L (eds) (2008) Lexi-
Comp drug database drug information handbook, 17th edn.
Lexi-Comp Information Management Service (LIMS), Hudson,
pp 15–16, 939–942, 1227, 1332–1335
13. Kelly WN (2008) How can I recognize an adverse drug event?
MedscapeCME Pharmacists
14. Naranjo C, Busto U, Sellers EM et al (1981) A method for
estimating the probability of adverse drug reactions. Clin
Pharmacol Ther 30:239–245
Matthew J. Geraci is a Clinical Pharmacist in the Emergency
Department at Baptist Medical Center Downtown in Jacksonville, FL
and a Clinical Assistant Professor of Pharmacy Practice with the
University of Florida. He completed his postgraduate residency at
the Mayo Clinic, Jacksonville, FL. He received his PharmD from the
University of Utah and a BS in Physics/Nuclear Engineering fromWest
Point.
Stacey L. McCoy is a Clinical Pharmacist in the Emergency
Department at Baptist Medical Center Downtown in Jacksonville,
FL and a Clinical Assistant Professor of Pharmacy Practice with the
University of Florida. She completed her postgraduate residency at St.
Joseph’s/Candler Hospital, Savannah, GA. She received her PharmD
from Mercer University and a BS/MS from Clark Atlanta University.
She is a Board Certified Pharmacotherapy Specialist.
Paul M. Crum is a Consulting Urologist at McIver Urological Clinic,
Riverside Office, in Jacksonville, FL. He completed his postgraduate
residency at the U.S. Naval Hospital in Philadelphia, PA and attended
medical school at the University of Pennsylvania. He is a Fellow of
the American College of Surgeons, Board Certified in Urology, and
member of the Society of Pediatric Urologists.
Rajnikant A. Patel is an Attending Physician with the Emergency
Resources Group at Baptist Medical Center in Jacksonville, FL. He
completed his postgraduate residency at King Edward VII Memorial
Hospital in Bombay, India; Albert Dock Hospital in London, UK; and
at the University Hospital of Jacksonville in FL. He attended medical
school at G.S. Medical College, University of Bombay in India and is
a Fellow of the American College of Emergency Physicians.
84 Int J Emerg Med (2010) 3:81–84
